Hesperadin Production Cost Reports

The report provides a detailed analysis essential for establishing a hesperadin production plant. It encompasses all critical aspects necessary for hesperadin production, including the cost of hesperadin production, hesperadin plant cost, hesperadin production costs, and the overall hesperadin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a hesperadin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Hesperadin is a small-molecule ATP-competitive inhibitor targeting Aurora B kinase with an IC50 of 250 nM. It has specialised applications in pharmaceutical and biotech research settings. It is utilised in laboratory environments to study mitotic processes by disrupting chromosome alignment, segregation, and histone H3 phosphorylation at Ser-10 (IC50 ~40 nM). It induces cell death pathways like paraptosis for anti-cancer drug discovery. It is also utilized in biochemical assay development and kinase inhibitor screening to support the identification and validation of new therapeutic targets.

Hesperadin's market growth is driven by its demand from academic and biotech labs studying mitotic processes and anti-cancer mechanisms, driven by broader R&D investments in targeted therapies amid rising cancer prevalence. Additionally, its potential role in antiviral research and other preclinical studies expands its application in laboratory and drug discovery settings, which contributes to market growth. The expansion of related inhibitors in nutraceutical expansion, citrus waste valorisation, antioxidant supplement demand, and vascular health formulations boost the market growth. However, supply chain disruptions, such as raw material shortages for kinase inhibitors or global logistics delays, impact industrial hesperadin procurement, along with institutional budget cycles and grant funding availability in academic/biotech settings that dictate order volumes.

Raw Material for Hesperadin Production

According to the hesperadin production plant project report, the various raw materials for hesperadin production include 2-iodoaniline, benzaldehyde, phenyl propiolic acid, and isocyanide.

Production Process of Hesperadin

The extensive hesperadin production cost report consists of the following major industrial production process:

1. Production via a stereoselective two-step process: The production process of hesperadin occurs via a stereoselective two-step procedure. It begins with a Ugi four-component reaction (Ugi-4CR) involving 2-iodoaniline, an aldehyde (e.g., benzaldehyde), phenyl propiolic acid, and an isocyanide in methanol, followed by stirring for 24 hours to form N-substituted-2-alkynamide intermediates. In the next step, the intermediate undergoes a palladium-catalysed domino Heck/Buchwald coupling with aniline under reflux for 7 hours. The final steps involve washing with brine, drying over sodium sulfate, solvent evaporation, and purification via silica gel column chromatography (hexane/ethyl acetate 10:3) to isolate hesperadin.

Properties of Hesperadin

Hesperadin is a synthetic small-molecule inhibitor of Aurora B kinase with a molecular formula of C20H19ClN6O3 and a molecular weight of 426.86 g/mol. It appears as a yellow to off-white solid powder with high lipophilicity suitable for cell-permeable assays, exhibiting low aqueous solubility (<1 mg/mL) that necessitates DMSO stock solutions (up to 100 mM) for lab use. It functions as an ATP-competitive antagonist, binding the kinase's catalytic cleft via its sulfonamide group (IC50 250 nM for Aurora B; 40 nM for H3 Ser-10 phosphorylation), while showing selectivity over other kinases like MKK1 in vivo. It shows stability under standard storage (-20 degree Celsius, protected from light) but sensitivity to prolonged exposure in solution.